Trials / Not Yet Recruiting
Not Yet RecruitingNCT07180771
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
A Phase II, Single-arm, Multicenter, Open Label Study to Evaluate Efficacy and Safety of BR101801 Monotherapy in Relapsed/Refractory Peripheral T-cell Lymphoma Patients
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).
Detailed description
This phase II study will evaluate the efficacy and safety of single-dose BR101801 once daily in patients with peripheral T-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BR101801 | Patients will receive 200mg capsules (100mg+100mg) |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
- First posted
- 2025-09-18
- Last updated
- 2026-01-28
Source: ClinicalTrials.gov record NCT07180771. Inclusion in this directory is not an endorsement.